Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial

Targeting Interferon-γ to Treat Atherosclerosis

Israel Gotsman, Andrew H. Lichtman
Download PDF
https://doi.org/10.1161/CIRCRESAHA.107.155838
Circulation Research. 2007;101:333-334
Originally published August 16, 2007
Israel Gotsman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew H. Lichtman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics

Jump to

  • Article
    • Acknowledgments
    • References
  • Info & Metrics
  • eLetters
Loading
  • atherosclerosis
  • cytokines
  • interferon-γ
  • gene therapy

See related article, pages 348–356

The chronic inflammatory nature of atherosclerotic disease is now widely appreciated. Abnormal deposition and oxidative modification of serum lipoproteins in arterial walls stimulates the recruitment of monocytes and their conversion into foam cells. Concurrently, both innate and adaptive immune responses are induced. Cytokines and growth factors produced as part of these responses lead to the remodeling of the arterial wall that typifies atherosclerotic lesions, including SMC accumulation and collagenous matrix deposition in the intima.1 The predominant inflammatory cells found in the atherosclerotic plaques are macrophages and T lymphocytes.2 The majority of T lymphocytes in atherosclerotic lesions are CD4+ T-helper cells expressing markers of activation.3 These activated T lymphocytes have been shown to be important in propagating the inflammatory processes that enhance lesion development.4,5 The majority of these T cells have a phenotype characteristic of the proinflammatory T-helper 1 (Th1) subset, and Th1-mediated immune responses have been shown to correlate with the development of atherosclerosis in mouse models.6–8

The signature cytokine produced by Th1 cells is interferon (IFN)γ. Immunohistochemical and in situ hybridization studies indicate that IFNγ is present in human atherosclerotic plaques.2,9–11 Numerous studies in mice have demonstrated a central role of IFNγ in atherosclerosis. Genetic ablation of IFNγ or IFNγ receptor (IFNγR) expression in mice significantly reduces atherosclerosis,12,13 whereas administration of exogenous IFNγ potentiates atherosclerosis.14 IFNγ has many different biologic effects that contribute to lesion development, including enhancement of antigen presenting capabilities of endothelium and macrophages, enhancement of inflammatory cell recruitment via upregulation of endothelial adhesion molecules, stimulation of proinflammatory cytokine and chemokine secretion by macrophages, production of reactive oxygen species by macrophages, and the inhibition of cholesterol efflux from foam cells.15 IFNγ also contributes to destabilization of mature lesions by blocking smooth muscle cell (SMC) proliferation and collagen synthesis and by stimulating matrix metalloproteinase synthesis by macrophages.

Given the central role of IFNγ in atherosclerotic-plaque pathology, therapeutically targeting this cytokine could reduce the atherosclerotic burden and/or enhance the stability of plaques. The study by Koga et al in the current issue of Circulation Research16 addresses this option in a mouse model. The study elegantly demonstrates that IFNγ neutralization, by repeated injections of a plasmid encoding a soluble INF-γR construct (sIFNγR), reduces lesion progression. In 1 experiment, apolipoprotein E (apoE)-deficient mice were fed a high-fat diet for 8 weeks and received 2 intramuscular injections of control or sIFNγR-encoding plasmid DNA after 4 and 6 weeks of the diet regimen before euthanasia. The efficacy of the sIFNγR treatment in neutralizing IFNγ was confirmed in a biological assay, and the effects of the treatment on aortic lesion size and phenotypes were assessed. The treatment was found to significantly reduce lesion size. Furthermore, the plaque burden reduction was accompanied by a change to a more stable phenotype with reduced lipid and macrophages and increased SMCs and collagen deposition. In support of a direct affect of IFNγ blocking, reduced phosphorylation of Stat1, a downstream signaling molecule activated through the IFNγR, was seen in the lesions of the treated mice. Koga et al also provide some mechanistic explanation for these findings. They show that sIFNγR treatment downregulates lesional gene expression of the proinflammatory molecules interleukin-1β, interleukin-6, vascular cell adhesion molecule-1, monocyte chemoattractant protein-1, and macrophage inflammatory protein-1α. All of these molecules have been shown to be important in the development of the atherosclerotic lesion. In addition, the treatment reduced the gene expression of matrix metalloproteinase-9 and -13, enzymes important in extracellular matrix degradation, while upregulating procollagen type I. These findings provide a plausible explanation for the stabilization of the plaque. They also show that CD40 and CD40L, which exert proatherogenic effects in mice, are downregulated in the lesions of the treated mice.

Although it is now well established that IFNγ plays a central role in the propagation of atherosclerosis and genetic ablation significantly reduces atherosclerosis, this is the first published study that targets IFNγ in a pharmacological manner (using a gene transfer technology) to treat atherosclerosis. The use of sIFNγR gene transfer and the effects of this approach on atherosclerotic lesion development and phenotype are of significant interest. This novel approach has several advantages. In experimental animals it avoids developmental compensations for mutant genes that may arise in gene knock out mice. The use of plasmid injection allows some control over the time course of IFNγ neutralization. Importantly, gene transfer is a potential treatment strategy in humans, and therefore this study helps in defines the feasibility of targeting a proatherogenic cytokine.

Although the prospect of targeting INF-γ as a potential therapeutic avenue for atherosclerosis, as suggested by this article, is very appealing, several issues must be addressed before such an approach can be considered in the clinical arena. In a second experiment focusing on what happens after treatment cessation, Koga et al fed the apoE−/− mice a high-fat diet for 16 weeks, and sIFNγR treatment was administered to 1 group at 4, 6, 8, and 12 weeks and administered to another group only at 4 and 6 weeks. In this experiment, lesion progression resumed, possibly even at a faster rate than in mock-treated animals, after sIFNγR treatment was stopped. This raises concerns about the potential limitations of cytokine blockade in general for the treatment of atherosclerosis, because temporary blockade of plaque-based inflammation apparently does not effectively remove the stimuli driving the inflammation or the cells that respond to these stimuli. Of course, IFNγ has a central role in the function of the adaptive immune response, and long-term systemic inhibition of IFNγ may result in increased susceptibility to intracellular infections and possibly neoplasia. As suggested by the authors, it is very appealing to consider local therapeutic avenues such as local delivery of recombinant sIFNγR protein using nanoparticles, thus avoiding the possible systemic side effects.

Another important finding of this study is the potential stabilizing affect of sIFNγR treatment on the atherosclerotic plaque. As the majority of acute coronary events are postulated to occur when unstable plaques rupture, stabilization of the lesion is of significant clinical importance. Koga et al demonstrated that sIFNγR-treated animals had a more stable phenotype, with reduced inflammatory cells and increased collagen and SMC content. Indeed, IFNγ has been shown to reduce collagen type I deposition by SMCs affecting the extracellular matrix17,18 and primes SMCs to Fas-induced apoptosis,19 undermining the stability of the atherosclerotic plaque and causing reduced stability of the lesion. However, there is evidence to suggest that IFNγ may have the reverse effect on vascular remodeling. IFNγ may directly cause SMC proliferation and activation,20 inhibit SMC apoptosis, and increase formation of neointimal proliferation after vascular injury.21 Indeed, in a recent publication by the same group, IFNγ blockade using the same sIFNγR agent used in the present study, caused reduced proliferation of intimal SMC, attenuating neointima formation in a rat model of vascular injury.22 Further work will be required to understand these conflicting effects of IFNγ blockade on neointimal SMC accumulation in different vascular pathologies.

Acknowledgments

Sources of Funding

This work was supported by NIH grant R01 HL87282 (to A.H.L).

Disclosures

None.

References

  1. ↵
    Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005; 352: 1685–1695.
    OpenUrlCrossRefPubMed
  2. ↵
    Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol. 1989; 135: 169–175.
    OpenUrlPubMed
  3. ↵
    Hansson GK, Jonasson L, Holm J, Claesson-Welsh L. Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain. Clin Exp Immunol. 1986; 64: 261–268.
    OpenUrlPubMed
  4. ↵
    Reardon CA, Blachowicz L, White T, Cabana V, Wang Y, Lukens J, Bluestone J, Getz GS. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21: 1011–1016.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000; 102: 2919–2922.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariety J, Nicoletti A. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2001; 104: 197–202.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Zhou X, Paulsson G, Stemme S, Hansson GK. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest. 1998; 101: 1717–1725.
    OpenUrlCrossRefPubMed
  8. ↵
    Buono C, Binder CJ, Stavrakis G, Witztum JL, Glimcher LH, Lichtman AH. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A. 2005; 102: 1596–1601.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Geng YJ, Holm J, Nygren S, Bruzelius M, Stemme S, Hansson GK. Expression of the macrophage scavenger receptor in atheroma. Relationship to immune activation and the T-cell cytokine interferon-gamma. Arterioscler Thromb Vasc Biol. 1995; 15: 1995–2002.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995; 92: 3893–3897.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Frostegard J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999; 145: 33–43.
    OpenUrlCrossRefPubMed
  12. ↵
    Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol. 2003; 23: 454–460.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997; 99: 2752–2761.
    OpenUrlCrossRefPubMed
  14. ↵
    Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol. 2000; 157: 1819–1824.
    OpenUrlCrossRefPubMed
  15. ↵
    Harvey EJ, Ramji DP. Interferon-gamma and atherosclerosis: pro- or anti-atherogenic? Cardiovasc Res. 2005; 67: 11–20.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Koga M, Kai H, Yasukawa H, Yamamoto T, Kawai Y, Kato S, Kusaba K, Kai M, Egashira K, Kataoka Y, Imaizumi T. Inhibition of progression and stabilization of plaques by postnatal interferon-γ function blocking in ApoE-knockout mice. Circ Res. 2007; 101: 348–356.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Buttice G, Miller J, Wang L, Smith BD. Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circ Res. 2006; 98: 472–479.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Xu Y, Wang L, Buttice G, Sengupta PK, Smith BD. Major histocompatibility class II transactivator (CIITA) mediates repression of collagen (COL1A2) transcription by interferon gamma (IFN-gamma). J Biol Chem. 2004; 279: 41319–41332.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Rosner D, Stoneman V, Littlewood T, McCarthy N, Figg N, Wang Y, Tellides G, Bennett M. Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. Am J Pathol. 2006; 168: 2054–2063.
    OpenUrlCrossRefPubMed
  20. ↵
    Tellides G, Tereb DA, Kirkiles-Smith NC, Kim RW, Wilson JH, Schechner JS, Lorber MI, Pober JS. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature. 2000; 403: 207–211.
    OpenUrlCrossRefPubMed
  21. ↵
    Zohlnhofer D, Richter T, Neumann F, Nuhrenberg T, Wessely R, Brandl R, Murr A, Klein CA, Baeuerle PA. Transcriptome analysis reveals a role of interferon-gamma in human neointima formation. Mol Cell. 2001; 7: 1059–1069.
    OpenUrlCrossRefPubMed
  22. ↵
    Kusaba K, Kai H, Koga M, Takayama N, Ikeda A, Yasukawa H, Seki Y, Egashira K, Imaizumi T. Inhibition of intrinsic interferon-gamma function prevents neointima formation after balloon injury. Hypertension. 2007; 49: 909–915.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
August 17, 2007, Volume 101, Issue 4
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Acknowledgments
    • References
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Targeting Interferon-γ to Treat Atherosclerosis
    Israel Gotsman and Andrew H. Lichtman
    Circulation Research. 2007;101:333-334, originally published August 16, 2007
    https://doi.org/10.1161/CIRCRESAHA.107.155838

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Targeting Interferon-γ to Treat Atherosclerosis
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Targeting Interferon-γ to Treat Atherosclerosis
    Israel Gotsman and Andrew H. Lichtman
    Circulation Research. 2007;101:333-334, originally published August 16, 2007
    https://doi.org/10.1161/CIRCRESAHA.107.155838
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured